Crossmark

Advancements in Antiviral Therapy: Favipiravir Sodium in Nasal Formulation

Crossref DOI link: https://doi.org/10.1208/s12249-024-02986-5

Published Online: 2024-11-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Darne, Priti https://orcid.org/0000-0002-2908-6309
Vidhate, Shankar https://orcid.org/0009-0009-1370-9442
Shintre, Somesh https://orcid.org/0009-0005-7669-7849
Wagdare, Somnath https://orcid.org/0009-0004-6282-0781
Bhamare, Dhiraj https://orcid.org/0009-0004-2683-2988
Mehta, Nisha https://orcid.org/0000-0002-4977-0191
Rajagopalan, Vishal https://orcid.org/0000-0002-2970-5747
Padmanabhan, Sriram https://orcid.org/0000-0001-8049-3703
License Information

Text and Data Mining valid from 2024-11-26

Version of Record valid from 2024-11-26
More Information

Article History

Received: 13 August 2024

Accepted: 29 October 2024

First Online: 26 November 2024

Declarations

:

: The authors declare no conflicts of interest.